MX339340B - Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico. - Google Patents

Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.

Info

Publication number
MX339340B
MX339340B MX2013011431A MX2013011431A MX339340B MX 339340 B MX339340 B MX 339340B MX 2013011431 A MX2013011431 A MX 2013011431A MX 2013011431 A MX2013011431 A MX 2013011431A MX 339340 B MX339340 B MX 339340B
Authority
MX
Mexico
Prior art keywords
activation
gastric cancer
her1
survival
stage
Prior art date
Application number
MX2013011431A
Other languages
English (en)
Other versions
MX2013011431A (es
Inventor
Sharat Singh
Phillip Kim
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013011431A publication Critical patent/MX2013011431A/es
Publication of MX339340B publication Critical patent/MX339340B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un método in vitro para predecir la supervivencia que tiene cáncer gástrico en etapa I después de la cirugía del tumor, caracterizado porque comprende: (a) determinar la presencia de activación o el nivel de activación de al menos dos analitos que comprenden cMTE y HER1 son co-activadas en la célula de cáncer obtenida del sujeto, en donde cMET y HER1 son co-activadas en la célula cancerosa; y (b) predecir la supervivencia del sujeto con base en la presencia de activación o el nivel de activación de los al menos dos analitos determinados en la etapa (a), en donde el sujeto se predice que tiene una peor supervivencia en comparación con sujetos con cáncer gástrico en etapa I con activación de cMET en ausencia de activación de HER1. Una composición que comprende un inhibidor de cMET y un inhibidor de HER1 para usarse en el tratamiento cáncer gástrico en etapa I en un sujeto, en donde cMET y HER1 son co-activadas en el cáncer gástrico en etapa I, y en donde el sujeto tiene peor supervivencia y/o pronóstico más deficiente en comparación con sujetos con cáncer gástrico en etapa I con activación de cMet en ausencia de activación de HER1. Figura 11.
MX2013011431A 2011-04-04 2012-04-04 Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico. MX339340B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471678P 2011-04-04 2011-04-04
US201261590787P 2012-01-25 2012-01-25
PCT/US2012/032206 WO2012138785A1 (en) 2011-04-04 2012-04-04 Methods for predicting and improving the survival of gastric cancer patients

Publications (2)

Publication Number Publication Date
MX2013011431A MX2013011431A (es) 2014-06-06
MX339340B true MX339340B (es) 2016-05-20

Family

ID=46000356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011431A MX339340B (es) 2011-04-04 2012-04-04 Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.

Country Status (15)

Country Link
US (2) US20140099300A1 (es)
EP (1) EP2694972B8 (es)
JP (1) JP2014517259A (es)
KR (1) KR20140020318A (es)
CN (1) CN103597354B (es)
AU (1) AU2012240242A1 (es)
CA (1) CA2831468A1 (es)
DK (1) DK2694972T3 (es)
ES (1) ES2639650T3 (es)
IL (1) IL228579A0 (es)
MX (1) MX339340B (es)
NZ (1) NZ615738A (es)
RU (1) RU2013148768A (es)
SG (2) SG10201601301RA (es)
WO (1) WO2012138785A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101327533B1 (ko) * 2012-12-11 2013-11-08 사회복지법인 삼성생명공익재단 환자 맞춤형 항암제 선별용 시스템
KR20160024639A (ko) 2014-08-26 2016-03-07 삼성전자주식회사 c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
CN105588943B (zh) * 2016-01-28 2018-03-02 山东省肿瘤防治研究院 一种胃癌患者外周血循环肿瘤细胞Her‑2基因的检测方法
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
TWI639430B (zh) * 2016-08-27 2018-11-01 中國醫藥大學 醫藥組合物用於製備治療胃癌藥物的用途
WO2020092860A1 (en) * 2018-11-01 2020-05-07 The Jackson Laboratory Gastric cancer treatments
WO2020100969A1 (ja) * 2018-11-14 2020-05-22 学校法人金沢医科大学 びまん性胃がんを治療するための医薬組成物
CN114594252A (zh) * 2020-12-03 2022-06-07 复旦大学附属中山医院 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用
KR20220078117A (ko) 2020-12-03 2022-06-10 원광대학교산학협력단 혈액샘플을 이용한 코로나 환자 사망률 예측 시스템 및 방법
JP2023023327A (ja) * 2021-08-05 2023-02-16 国立大学法人大阪大学 腫瘍のサブタイプ決定方法及びその応用、並びにサブタイプ決定のための方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
CA2170873A1 (en) 1993-09-03 1995-03-09 Dariush Davalian Fluorescent oxygen channeling immunoassays
WO2008036802A2 (en) 2006-09-21 2008-03-27 Prometheus Laboratories Inc. Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
BRPI0717416A2 (pt) * 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
BRPI0813583A2 (pt) 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
NZ600339A (en) 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
AU2010233993A1 (en) * 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
EP2430443B1 (en) 2009-05-14 2018-06-27 Pierian Holdings, Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010273319B2 (en) * 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
MX337666B (es) 2009-10-20 2016-03-14 Nestec Sa Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
US9175084B2 (en) * 2010-04-02 2015-11-03 Fujirebio Inc. Diagnostic marker for effect of anticancer agent

Also Published As

Publication number Publication date
EP2694972B1 (en) 2017-06-21
AU2012240242A1 (en) 2013-10-10
KR20140020318A (ko) 2014-02-18
MX2013011431A (es) 2014-06-06
JP2014517259A (ja) 2014-07-17
SG193626A1 (en) 2013-10-30
US20170285044A1 (en) 2017-10-05
CN103597354B (zh) 2016-04-20
SG10201601301RA (en) 2016-03-30
CN103597354A (zh) 2014-02-19
EP2694972A1 (en) 2014-02-12
EP2694972B8 (en) 2017-08-16
NZ615738A (en) 2015-11-27
DK2694972T3 (en) 2017-10-02
IL228579A0 (en) 2013-12-31
US20140099300A1 (en) 2014-04-10
CA2831468A1 (en) 2012-10-11
RU2013148768A (ru) 2015-05-10
WO2012138785A1 (en) 2012-10-11
ES2639650T3 (es) 2017-10-27

Similar Documents

Publication Publication Date Title
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
AR055316A1 (es) Metodos para la identificacion de tumores que responden al tratamiento con inhibidores de dimerizacion de her (hdis)
MX378293B (es) Metodos in vitro para correlacionar el nivel de st2 soluble y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular.
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
MX2016003245A (es) Calreticulina mutante para la diagnosis de malignidades mieloides.
PH12015502613B1 (en) Biological markers useful in cancer immunotherapy
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
PH12015500110A1 (en) Inhibitors of alpha-crystallin aggregation for the treatment of cataract
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
ES2721639T3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
MX362041B (es) Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
MX2017012320A (es) Estandares de antigeno prostatico y sus usos.
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
BR112013009143A2 (pt) método in vitro, uso e invenção

Legal Events

Date Code Title Description
FG Grant or registration